Vertex Pharmaceuticals (VRTX) – Investment Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Vertex Pharmaceuticals (NASDAQ: VRTX) recently:

• 12/10/2025 – Vertex Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $460.00 to $515.00. They now have an “overweight” rating on the stock.
• 12/5/2025 – Vertex Pharmaceuticals was given a new $564.00 price target on by analysts at Morgan Stanley.
• 12/4/2025 – Vertex Pharmaceuticals was upgraded by analysts at UBS Group AG to a “strong-buy” rating.
• 12/3/2025 – Vertex Pharmaceuticals was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $516.00 price target on the stock, up previously from $438.00.
• 11/13/2025 – Vertex Pharmaceuticals is now covered by analysts at Scotiabank. They set a “sector outperform” rating and a $495.00 price target on the stock.
• 11/12/2025 – Vertex Pharmaceuticals was upgraded by analysts at Scotiabank to a “strong-buy” rating.
• 11/7/2025 – Vertex Pharmaceuticals had its price target lowered by analysts at UBS Group AG from $553.00 to $546.00. They now have a “buy” rating on the stock.
• 11/4/2025 – Vertex Pharmaceuticals had its price target lowered by analysts at Stifel Nicolaus from $455.00 to $445.00. They now have a “hold” rating on the stock.
• 11/4/2025 – Vertex Pharmaceuticals had its price target raised by analysts at Barclays PLC from $408.00 to $414.00. They now have an “equal weight” rating on the stock.
• 11/4/2025 – Vertex Pharmaceuticals had its price target lowered by analysts at Royal Bank Of Canada from $423.00 to $415.00. They now have a “sector perform” rating on the stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $456.00, for a total value of $6,384,000.00. Following the completion of the sale, the executive vice president owned 37,725 shares of the company’s stock, valued at $17,202,600. This represents a 27.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $449.20, for a total transaction of $28,650,425.20. Following the transaction, the chairman directly owned 24,026 shares in the company, valued at approximately $10,792,479.20. The trade was a 72.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 151,073 shares of company stock worth $67,326,816 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.